Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Jiangsu Chia Tai Tianqing Pharmaceutical Group patents BCR-ABL inhibitors

Aug. 11, 2021

First patient dosed in phase I study of APL-102

Aug. 10, 2021

New PIN1 inhibitors discovered at Pimedbio, DGMIF

Aug. 10, 2021

Shanghai Hengrui Pharmaceutical, Jiangsu Hengrui Medicine patent ATR kinase inhibitors

Aug. 10, 2021

Korea Institute of Science and Technology identifies TNK2/MAP4K2 inhibitors

Aug. 10, 2021

First patient dosed in phase Ib/II study of AVB-500 in pancreatic adenocarcinoma

Aug. 10, 2021

Antengene and MindRank AI collaborate to advance difficult-to-drug molecular targets

Aug. 9, 2021

New SHP-2 inhibitors identified at Beijing Innocare Pharmaceutical Technology

Aug. 9, 2021

Jiangsu Hengrui Medicine, Shanghai Hengrui Pharmaceutical patent PROTACs targeting cereblon

Aug. 9, 2021

FDA places partial clinical hold on Aprea's myeloid malignancy programs

Aug. 6, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 8, 2026.
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
In the clinic for July 6, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Arcus, Genentech, Merck, Myriad, Otsuka, Partner, Revolution, Treos.